Erasca (ERAS) Accumulated Expenses (2020 - 2026)
Erasca's (ERAS) quarterly Accumulated Expenses came in at $6.5 million in Q1 2026, up 12.59% YoY from $5.8 million in Q1 2025, and down 45.78% on a QoQ basis from $12.1 million in Q4 2025.
Erasca (ERAS) Accumulated Expenses (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Accumulated Expenses data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Accumulated Expenses rose 12.59% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 12.59% YoY) and the FY2025 annual result came in at $12.1 million, up 13.35% from the prior year.
- Accumulated Expenses declined to $6.5 million in Q1 2026, from $12.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $24.3 million in Q4 2022 to a low of $4.6 million in Q1 2022.
- A 5-year average of $12.9 million and a median of $10.7 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 546.04% — and 2023, when it plunged 68.4%.
- Tracing ERAS's Accumulated Expenses over 5 years: stood at $24.3 million in 2022, then plunged by 57.63% to $10.3 million in 2023, then advanced by 3.3% to $10.7 million in 2024, then rose by 13.35% to $12.1 million in 2025, then slumped by 45.78% to $6.5 million in 2026.
- The last three Accumulated Expenses figures came in at $6.5 million (Q1 2026), $12.1 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.11 Mn |
| Mar 31, 2026 | 6.55 Mn |
| Dec 31, 2025 | 12.07 Mn |
| Sep 30, 2025 | 8.94 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Mar 31, 2025 | 5.81 Mn |
| Dec 31, 2024 | 10.65 Mn |
| Sep 30, 2024 | 23.17 Mn |
| Jun 30, 2024 | 18.47 Mn |
| Mar 31, 2024 | 16.58 Mn |
| Dec 31, 2023 | 10.31 Mn |
| Sep 30, 2023 | 19.21 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Mar 31, 2023 | 19.05 Mn |
| Dec 31, 2022 | 24.34 Mn |
| Sep 30, 2022 | 7.10 Mn |
| Jun 30, 2022 | 19.83 Mn |
| Mar 31, 2022 | 4.57 Mn |
| Dec 31, 2021 | 7.28 Mn |
| Sep 30, 2021 | 4.71 Mn |